DEFA14A: Alzamend Neuro Corrects Proxy Statement for 2025 Annual Meeting

Alzamend Neuro files a supplement to its proxy statement to correct an error related to an adjournment proposal inadvertently included on the proxy card.

Summary

• Alzamend Neuro, Inc. is supplementing its proxy statement for the annual meeting of stockholders to be held on April 25, 2025.
• The supplement corrects an error where the proxy card inadvertently included a fifth proposal regarding a potential adjournment of the annual meeting.
• This adjournment proposal was not included in the original proxy statement.
• The company states that all other information in the proxy card is correct.
• Shareholders who have already voted do not need to vote again unless they wish to change or revoke their prior vote.
• The board of directors recommends voting FOR all nominees and proposals 2-4.
• Proposal 2 is to ratify the selection of Haskell & White LLP as the company's independent registered public accounting firm for the fiscal year ending April 30, 2025.
• Proposal 3 is to approve the conversion of Series C convertible preferred stock into common stock and warrants for a total purchase price of up to $5,000,000, less a 5% discount.
• Proposal 4 is to approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the common stock by a ratio of not less than one-for-two and not more than one-for-ten at any time prior to April 24, 2026.

Sentiment

Score: 7

Explanation: The document is primarily procedural, correcting an error and outlining standard proposals for shareholder vote. The sentiment is neutral to slightly positive due to the proactive correction of the error.

Positives

• The company is proactively addressing and correcting an error in its proxy statement.
• Shareholders have multiple options for voting (online, phone, mail).
• The board provides clear recommendations on how to vote on each proposal.

Negatives

• The proxy card initially contained an error, which could have caused confusion among shareholders.

Risks

• The reverse stock split (Proposal 4) could be perceived negatively by some investors if implemented.
• Failure to obtain shareholder approval for the proposals could impact the company's plans.

Future Outlook

The document outlines key proposals for shareholder vote, including a potential reverse stock split and the conversion of preferred stock, which could impact the company's capital structure and stock price.

Management Comments

• The Board of Directors unanimously recommends a vote FOR all the nominees listed and FOR Proposals 2 ? 4.

Industry Context

This announcement is a routine part of corporate governance, ensuring shareholders have the opportunity to vote on key decisions affecting the company's direction and financial structure. The reverse stock split is a common strategy for companies seeking to increase their stock price and maintain listing requirements.

Comparison to Industry Standards

• Reverse stock splits are a common corporate action, particularly for companies trading at low share prices, similar to actions taken by companies like Cassava Sciences (SAVA) in the past to maintain Nasdaq compliance.
• The proposal to ratify the selection of an independent auditor is standard practice, aligning with the procedures followed by most publicly traded companies, such as Biogen (BIIB) and Eli Lilly (LLY).

Stakeholder Impact

• Shareholders will be directly impacted by the outcome of the votes on the proposals, particularly the reverse stock split and the conversion of Series C preferred stock.
• The company's employees and other stakeholders could be indirectly affected by changes in the company's financial structure and stock price.

Next Steps

• Shareholders will vote on the proposals outlined in the proxy statement at the annual meeting on April 25, 2025.
• The company will implement the approved proposals, including the reverse stock split (if approved) and the conversion of Series C preferred stock.

Key Dates

Keywords

proxy statement, annual meeting, Alzamend Neuro, reverse stock split, Series C preferred stock, conversion, warrants, election of directors, auditor ratification